Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells | PLOS ONE
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy | Arthritis Research & Therapy | Full Text
Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group - eClinicalMedicine
Comparison of the two tocilizumab strategies used in the economic... | Download Scientific Diagram
Pharmaceutics | Free Full-Text | Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19
Tocilizumab: Uses, Interactions, Mechanism of Action | DrugBank Online
761037Orig1s000
JCM | Free Full-Text | The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies
![Rapid Evidence Review: Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation. [v6.0]](https://www.lenus.ie/bitstream/handle/10147/628004/COVID-19_Evidence_Review_Group_Tocilizumab_V6_Final_Version.pdf.jpg?sequence=8&isAllowed=y "Rapid Evidence Review: Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation. [v6.0]")
Rapid Evidence Review: Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation. [v6.0]
Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model - ScienceDirect
Actemra® 20 mg/mL, concentrate for solution for intravenous (IV) infusion
Unravelling the potentialities of tocilizumab for the development of a potential immunotherapeutic regimen against COVID-19—A narrative review
Tocilizumab Effect in COVID-19 Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials
The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19 | Bentham Science
Health Product InfoWatch: October 2022 - Canada.ca
Full article: Tocilizumab (Actemra)
Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm | Nature Communications
Cureus | High-Dose Dexamethasone Versus Tocilizumab in Moderate to Severe COVID-19 Pneumonia: A Randomized Controlled Trial | Article
Sequence coverage of the heavy chain and light chain of originator... | Download Scientific Diagram
Tocilizumab Effect in COVID-19 Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials
Pharmacokinetic /Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19 | medRxiv
Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial - American Journal of Transplantation
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ
